Dr. McDermott Discusses the Future of Immune Checkpoints in RCC

David F. McDermott, MD
Published: Monday, Mar 13, 2017

David F. McDermott, MD, Beth Israel Deaconess Medical Center, discusses the future of immunotherapies in the treatment of patients with kidney cancer.

Atezolizumab (Tecentriq) may have an impact in the frontline setting with previously untreated patients, says McDermott. If successful, patients might not have to go on to receive further treatment.

In the adjuvant setting, checkpoint inhibitors also look extremely promising as trials in melanoma improved survival. Currently, these trials are ongoing in kidney cancer for patients who have recently undergone surgery. McDermott urges oncologists to look for these trials, as they have potential to improve survival for these patients.
 
David F. McDermott, MD, Beth Israel Deaconess Medical Center, discusses the future of immunotherapies in the treatment of patients with kidney cancer.

Atezolizumab (Tecentriq) may have an impact in the frontline setting with previously untreated patients, says McDermott. If successful, patients might not have to go on to receive further treatment.

In the adjuvant setting, checkpoint inhibitors also look extremely promising as trials in melanoma improved survival. Currently, these trials are ongoing in kidney cancer for patients who have recently undergone surgery. McDermott urges oncologists to look for these trials, as they have potential to improve survival for these patients.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x